Patient Inclusion Criteria

At least 18 years of age; CD4 cell count of greater than 400 cells; plasma HIV-1 RNA less than 50 copies/mL on two occasions: one within the six weeks prior to starting Baseline and the other during Baseline; history of virological success with suppression of HIV RNA level below 50 copies/mL during the last nine months documented a minimum of two times during the last ten months or a minimum of three times during the last fifteen months while patient is receiving a highly active antiretroviral therapy (HAART) regimen; during the four months prior to starting Baseline, continuing through Baseline and the 64 week study period, the HAART regimen must remain unchanged and contain at least one of the following ten anti-retroviral drugs: abacavir (Ziagen), zidovudine (Retrovir) AZT, zalcitabine (Hivid) ddC, didanosine (Videx) ddl, stavudine (Zerit) d4T, efavirenz (Sustiva), indinavir (Crixivan), ritonavir (Norvir), nelfinavir (Viracept), amprenavir (Agenerase); only one HIV plasma RNA level greater than 50, but less than 100 copies/mL is permitted during the four month period immediately prior to starting Baseline; Karnofsky performance status of at least 70; the following laboratory parameters within 21 days prior to treatment: haemoglobin greater than 9.2 g/dL for men and greater than 8.9 g/dL for women; neutrophil count greater than 1000; platelet count greater than 75,000; aspartate/alanine transaminase less than 4.0 x upper limit of normal (ULN); serum creatinine less than 1.5 x ULN or a creatinine clearance greater than 50 mL/min; ability and willingness to give written informed consent; for females with child bearing potential: A negative serum pregnancy test within 14 days prior to randomisation (females of child bearing potential agree to use an effective means of contraception); completed any elective routine immunisations (including influenza vaccination) eight or more weeks prior to first dose of study drug.

Patient Exclusion Criteria

Active malignancy or history of malignancy other than minimal Kaposi sarcoma or basal cell carcinoma; inadequately controlled seizure disorder, history of AIDS, prior mismatched double-stranded RNA therapy (rintatolimod).